7:30 am Morning Coffee & Registration
8:20 am Chairs Opening Remarks
Aligning Regulatory Expectations with Process Development & CMC Requirements to Accelerate mRNA Platform Advancement
8:30 am Fireside Chat: Bridging Regulatory Gaps in Manufacturing of Cancer Vaccines in Clinical Phases: Aligning Process Development & CMC to Achieve GMP Certification & Tech Transfer Readiness
9:30 am Designing the Ideal mRNA Platform: How to Align with CEPI’s Vision for Rapid Outbreak Response
10:00 am Morning Break
Track 1: Research Scale
Enhancing mRNA Stability to Extend Shelf Life, Improve Translation, & Support Global Distribution
11:00 am Leveraging Identity Assays to Enhance Drug Substance Stability to Preserve Integrity & Extend Usability Across Development Stages
Christine Tkaczyk, Director, AstraZeneca
11:30 am Achieving Thermostability Through Lyophilization to Extend Shelf Life & Improve Storage Flexibility
Brian Luk, Senior Scientist II, Arcturus Therapeutics
12:00 pm Harnessing Modifications to Enhance Drug Product Stability & Reduce Cold Chain Burden
Manasa Chillara, PhD Candidate, Rensselaer Polytechnic Institute
Track 2: IND Enabling & Clinical Scale
12:30 pm Lunch Break
Track 1: Research Scale
Evolving Formulation Strategies to Improve Stability, Delivery Precision & Modality Compatibility for Increased Patient Use
1:30 pm Engineering Next-Generation LNP Design to Maximise Payload, Encapsulation Efficiency & Mechanistic Understanding
Daryl Drummond, Chief Scientific Officer, Akagera Medicines
2:00 pm Reimagining RNA Delivery: Breaking the LNP Barrier with Peptide-Based Vectors
Gilles Divita, CEO, Divincell
2:30 pm Exploring Non-Lipid-Based Nanoparticles to Expand Delivery and Storage Options to Improve Patient Accessibility
Kinkini Roy, Associate Director, Drug Product Development, Aviceda Therapeutics
Track 2: IND Enabling & Clinical Scale